enVVeno Medical

Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus estimates on the bottom line, with a GAAP net loss of -$3.60M compared to the expected -$4.69M. As a late-stage developmental company, revenue remains at $0.00, in line with expectations. Operating expenses were well-managed, leading to an EBIT beat of +$0.87M (+18.72%) vs. consensus, primarily driven by a 59% YoY reduction in SG&A expenses. Management highlighted sufficient liquidity to fund operations into Q3 2027, despite an anticipated increase in cash burn to $4M-$5M per quarter in H2 2026.